EUVIMEDEUVIMED entdecken
Crossref

Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy

The Medical Letter on Drugs and Therapeutics · 25.05.2026 · 68 (1755) · 85-87

DOI: 10.58347/tml.2026.1755c ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 25.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aficamten (Myqorzo – Cytokinetics), an oral cardiac myosin inhibitor, has been approved by the FDA to improve functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). It is the second cardiac myosin inhibitor to be approved in the US for this indication; mavacamten (Camzyos) was approved in 2022.

Schlagwörter

Stichwörter der Autor:innen

CamzyosMyqorzoadverse effectsaficamtendosagedrug interactionsefficacylactationmavacamtenobstructive hypertrophic cardiomyopathypregnancysafety

Zitieren

APA

(2026). Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy. The Medical Letter on Drugs and Therapeutics, 68(1755), 85-87. https://doi.org/10.58347/tml.2026.1755c

Vancouver

Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy. The Medical Letter on Drugs and Therapeutics. 2026;68(1755):85-87. doi:10.58347/tml.2026.1755c

BibTeX
@article{euvimed2026,
  title = {Aficamten (Myqorzo) for Obstructive Hypertrophic Cardiomyopathy},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1755},
  pages = {85--87},
  doi = {10.58347/tml.2026.1755c}
}
Kostenlos starten →